Affordable Access

deepdyve-link
Publisher Website

Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG).

Authors
  • Graeter, Stefanie1
  • Simon, Hans-Uwe2
  • von Gunten, Stephan3
  • 1 Institute of Pharmacology, University of Bern, Bern, Switzerland. , (Switzerland)
  • 2 Institute of Pharmacology, University of Bern, Bern, Switzerland; Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia. , (Switzerland)
  • 3 Institute of Pharmacology, University of Bern, Bern, Switzerland. Electronic address: [email protected] , (Switzerland)
Type
Published Article
Journal
Pharmacological Research
Publisher
Elsevier
Publication Date
Apr 01, 2020
Volume
154
Pages
104168–104168
Identifiers
DOI: 10.1016/j.phrs.2019.02.007
PMID: 30738127
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Granulocytes are key effector cells of the innate immune system that cause substantial by-stander tissue damage in a broad range of inflammatory disorders. Specific antibodies with the potential to regulate granulocyte survival are present in polyclonal intravenous immunoglobulin (IVIG) preparations and may contribute to the anti-inflammatory effects of high-dose IVIG therapy. Here, we discuss idiosyncratic characteristics of antibodies to FAS and Siglecs contained in IVIG pertaining to granulocyte death regulation and highlight implications for research and clinical practice. Copyright © 2019 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times